白细胞介素 -6阻断剂在类风湿关节炎的治疗应用

摘要

Rheumatoid arthritis ( RA ) is a systemic inflammatory autoimmune disease. The imbalance of immune system is crucial to the pathogenesis of this disease. Therefore, inhibiting of inflammation is an important approach in the treatment of RA. Interleukin-6 ( IL-6 ) is a pleiotropic cytokine which is closely related with RA. Blocking the signaling pathway of IL-6 is a new strategy of treating this disease. Tocilizumab is a humanized anti-IL-6 receptor monoclonal antibody. Its effectiveness and safety in patients with RA have been proved by a series of randomized double-blind placebo-controlled clinical trials. This agent may bring us a new perspective for the treatment of RA.%类风湿关节炎(rheumatoid arthritis,RA)是一种系统性炎症性自身免疫性疾病.免疫系统的失调在其发病中起着重要作用,因而抑制炎症反应是治疗RA的重要手段.白细胞介素6(interleukin-6,IL-6)是多功能细胞因子,与RA的发病有着密切联系.阻断IL-6信号传导通路是RA治疗的一个新策略.托珠单抗(Tocilizumab)是人源化IL-6受体单克隆抗体,一系列随机双盲安慰剂对照临床试验已显示其对于RA患者的疗效和安全性.这一药物可能会为RA的治疗带来新的曙光.